3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
2
NIH
2
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
2
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
93
Carcinoma, Non-Small-Cell Lung
46
Neoplasms
33
Carcinoma, Renal Cell
24
Neoplasm Metastasis
16
Colorectal Neoplasms
13
Carcinoma, Hepatocellular
12
Small Cell Lung Carcinoma
9
Prostatic Neoplasms
9
Lung Neoplasms
9
Diabetes Mellitus, Insulin-Dependent, 12
9
Advanced Cancer
9
Squamous Cell Carcinoma of Head and Neck
8
Uveal Melanoma
7
Stomach Neoplasms
7
Skin Neoplasms
7
Mesothelioma
7
Kidney Neoplasms
7
Carcinoma, Transitional Cell
7
Recurrence
6
Pancreatic Neoplasms
6
Liver Neoplasms
6
Triple Negative Breast Neoplasms
5
Sarcoma
5
Ovarian Neoplasms
5
Head and Neck Neoplasms
5
Endometrial Neoplasms
5
Breast Neoplasms
5
Uterine Cervical Neoplasms
4
Solid Tumor
4
Interventions
pembrolizumab
2
Ipilimumab
2
Doxorubicin
2
soblidotin
1
reolysin
1
olaratumab
1
futibatinib
1
envafolimab
1
brigimadlin
1
belinostat
1
Injections
1
Immune Checkpoint Inhibitors
1
Ifosfamide
1
Histamine H2 Antagonists
1
Gemcitabine
1
Fluorouracil
1
Famotidine
1
Erlotinib Hydrochloride
1
Docetaxel
1
Angptl4 protein, mouse
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Histiocytoma, Malignant Fibrous
×
Ipilimumab
×
Clear all
NCT03752398
2024-07-05
DUET-3
Xencor, Inc.
Phase 1
Completed
198 enrolled
NCT04480502
2024-05-17
ENVASARC
Tracon Pharmaceuticals Inc.
Phase 2
Unknown
207 enrolled